Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults

Vaccine

Volumn 29, Issue 17, 2011, Pages 3183-3191

  Crum Cianflone, Nancy F ^a,b   Iverson, Erik ^a,c   Defang, Gabriel ^d   Blair, Patrick J ^b   Eberly, Lynn E ^a,c   Maguire, Jason ^a   Ganesan, Anuradha ^a,e   Faix, Dennis ^b   Duplessis, Christopher ^b   Lalani, Tahaniyat ^b   Whitman, Timothy ^a,e   Brandt, Carolyn ^a,b   Macalino, Grace ^a   Millar, Eugene V ^a   Burgess, Timothy ^a,d  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d NAVAL MEDICAL RESEARCH CENTER   (United States)

^e WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Durability; HIV; Influenza; Long term immunity; Pandemic 2009 H1N1; Vaccine responses

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INFLUENZA VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA A (H1N1); MAJOR CLINICAL STUDY; MALE; PANDEMIC; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS STRAIN;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HIV INFECTIONS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; TIME FACTORS; YOUNG ADULT;

EID: 79954570396     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.040     Document Type: Article

References (49)

1. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361:2424-2435.
2. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response after one dose of a monovalent influenza A (H1N1) 2009 vaccine - preliminary report. N Engl J Med 2009, 361:2405-2413.
3. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361:2414-2423.
4. Nolan T., McVernon J., Skeljo M., Richmond P., Wadia U., Lambert S., et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: A randomized trial. JAMA 2010, 303:37-46.
5. Liang X.F., Wang H.Q., Wang J.Z., Fang H.H., Wu J., Zhu F.C., et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010, 375:56-66.
6. Plennevaux E., Sheldon E., Blatter M., Reeves-Hoché M.K., Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375:41-48.
7. Vajo Z., Tamas F., Sinka L., Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 2010, 375:49-55.
8. Neuzil K.M., Reed G.W., Mitchel E.F., Griffin M.R. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 1999, 281:901-907.
9. Kunisaki K., Janoff E. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009, 9:493-504.
10. Lin J.C., Nichol K.L. Excess mortality due to pneumonia or influenza during influenza seasons among person with acquired immunodeficiency syndrome. Arch Intern Med 2001, 161:441-446.
11. Safrin S., Rush J.D., Mills J. Influenza in patients with human immunodeficiency virus infection. Chest 1990, 98:33-37.
12. Couch R.B., Kasel J.A. Immunity to influenza in man. Ann Rev Microbiol 1983, 37:529-549.
13. Tebas P., Frank I., Lewis M., Quinn J., Zifchak L., Thomas A., et al Center for AIDS research and clinical trials unit of the University of Pennsylvania poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS 2010, 24:2187-2192.
14. Crum-Cianflone N.F., Eberly L., Duplessis C., Maguire J., Ganesan A., Faix D., et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immune compromised population: a prospective study comparing HIV-infected to HIV-uninfected adults. Clin Infect Dis 2011, 52:138-146.
15. Bickel M., Wieters I., Khaykin P., Nisius G., Haberl A., Stephan C., et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 2010, 24:F31-35.
16. Tasker S.A., Treanor J.J., Paxton W.B., Wallace M.R. Efficacy of influenza vaccination in HIV-infected persons A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999, 131:430-433.
17. Kroon F.P., van Dissel J.T., de Jong J.C., Zwinderman K., van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000, 18:3040-3049.
18. Kroon F.P., Rimmelzwaan G.F., Roos M.T., Osterhaus A.D., Hamann D., Miedema F., et al. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS 1998, 12:F217-223.
19. Anema A., Mills E., Montaner J., Brownstein J.S., Cooper C. Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis. HIV Medicine 2008, 9:57-61.
20. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361:1945-1952.
21. Centers for Disease Control and Prevention (CDC). Updated interim recommendations-HIV-infected adults and adolescents: considerations for clinicians regarding 2009 H1N1 influenza. ; 2010 [accessed 16.03.10]. http://www.cdc.gov/h1n1flu/guidance_hiv.htm.
22. CDC protocol of realtime RTPCR for influenza A (H1N1). ; 2010 [accessed 11.06.09]. http://www.who.int/csr/resources/publications/swineflu/realtimeptpcr/en/index.html.
23. Hobson D., Curry R.L., Beare A.S., Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972, 70:767-777.
24. Hannoun C., Megas F., Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004, 103:133-138.
25. Kendal A.P., Pereira M.S., Skehel J.J. Concepts and procedures for laboratory-based influenza surveillance 1982, World Health Organization;, Geneva.
26. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37:937-943.
27. CDC. Updated CDC Estimates of 2009 H1N1 Influenza Cases, Hospitalizations and Deaths in the United States, April 2009 - April 10, 2010. ; 2010 [accessed 01.08.10]. http://www.cdc.gov/h1n1flu/estimates_2009_h1n1.htm.
28. Louie J.K., Acosta M., Winter K., Jean C., Gavali S., Schechter R., et al. California Pandemic (H1N1) Working group Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009, 302:1896-1902.
29. Oliveira W., Carmo E., Penna G., Kuchenbecker R., Santos H., Araujo W., et al. Surveillance Team for the pandemic influenza A(H1N1) 2009 in the Ministry of Health Pandemic H1N1 influenza in Brazil: analysis of the first 34,506 notified cases of influenza-like illness with severe acute respiratory infection (SARI). Euro Surveill 2009, 14:19362.
30. Riera M., Payeras A., Marcos M.A., Viasus D., Farinas M.C., Segura F., et al. Clinical presentation and prognosis of the 2009 H1N1 influenza A infection in HIV-1-infected patients: a Spanish multicenter study. AIDS 2010, 24:2461-2467.
31. Fiore A.E., Uyeki T.M., Broder K., Finelli L., Euler G.L., Singleton J.A., et al. Centers for disease control and prevention (CDC) prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010, 59:1-62.
32. Miotti P.G., Nelson K.E., Dallabetta G.A., Farzadegan H., Margolick J., Clements M.L. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA 1989, 262:779-783.
33. Glesby M.J., Hoover D.R., Farzadegan H., Margolick J.B., Saah A.J. The effect of influenza vaccination on human immunodeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study. J Infect Dis 1996, 174:1332-1336.
34. Yamanaka H., Teruya K., Tanaka M., Kikuchi Y., Takahashi T., Kimura S., et al. HIV/influenza vaccine study team efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Def Syndr 2005, 39:167-173.
35. Fuller J.D., Craven D.E., Steger K.A., Cox N., Heeren T.C., Chernoff D. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis 1999, 28:541-547.
36. Durando P., Fenoglio D., Boschini A., Ansaldi F., Icardi G., Sticchi L., et al. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol 2008, 15:253-259.
37. Center for Disease Control and Prevention. Inactivated influenza vaccine: what you need to know, 2010-2011. ; 2010 [accessed 20.10.10]. http://www.cdc.gov/vaccines/pubs/vis/default.htm.
38. Foy H.M., Cooney M.K., McMahan R. A Hong Kong influenza immunity three years after immunization. JAMA 1973, 226:758-761.
39. Lerman S.J., Wright P.F., Patil K.D. Antibody decline in children following A/New Jersey/76 influenza virus immunization. J Pediatr 1980, 96:271-274.
40. Ambrose C.S., Yi T., Walker R.E., Connor E.M. Duration of protection provided by live attenuated influenza vaccine in children. Pediatr Infect Dis J 2008, 27(8):744-748. Aug.
41. Clark A., Potter C.W., Jennings R., Nicholl J.P., Langrick A.F., Schild G.C., et al. A comparison of live and inactivated influenza A (H1N1) virus vaccines 2. Long-term immunity. J Hyg (Lond) 1983, 90:361-370.
42. Cate T.R., Couch R.B., Parker D., Baxter B. Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccines - 1978. Rev Infect Dis 1983, 5:737-747.
43. Noble G.R., Kaye H.S., O'Brien R.J., Kendal A.P., Bregman D.J., Wright P.F., et al. Persistence of influenza A/New Jersey/76 (Hsw1N1) antibody one year after vaccination. Dev Biol Stand 1977, 39:253-260.
44. Skowronski D.M., Tweed S.A., De Serres G. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant?. J Infect Dis 2008, 197:490-502.
45. Landrum M.L., Huppler Hullsiek K., Ganesan A., Weintrob A.C., Crum-Cianflone N.F., Barthel R.V., et al. Hepatitis B, vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine 2009, 27:4731-4738.
46. Søgaard O.S., Schønheyder H.C., Bukh A.R., Harboe Z.B., Rasmussen T.A., Ostergaard L., et al. Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy. AIDS 2010, 24:1315-1322.
47. Madhi S.A., Maskew M., Koen A., Kuwanda L., Besselaar T.G., Naidoo D., et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis 2011, 52:128-137.
48. Metzgar D., Baynes D., Myers C.A., Kammerer P., Unabia M., Faix D.J., et al. Initial identification and characterization of an emerging zoonotic influenza virus prior to pandemic spread. J Clin Microbiol 2010, 48:4228-4234.
49. Hymas W.C., Mills A., Ferguson S., Langer J., She R.C., Mahoney W., et al. Development of a multiplex real-time RT-PCR assay for detection of influenza A, influenza B, RSV and typing of the 2009-H1N1 influenza virus. J Virol Methods 2010, 167:113-118.